ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it had filed with the Autorité des Marchés Financiers (AMF) its half-year report for the six-month period ended June 30, 2021.
The half-year financial report is available in the Investors section of the Company’s corporate website (www.erytech.com).